Level C· Early human research exploring benefitsCase Report / SeriesEurope PMCOpen access

De Novo Heterozygous <i>KDM3B</i> Variants Expand the Mutational Spectrum of Diets-Jongmans Syndrome: Case Series and Literature Review

Miao H., Zhang T., Chen S., Xu X., Fang K., Wu D.

Case Report / Series on Face & Skin, published in Genes (Basel) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Genes (Basel) (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41898828
PMCID
PMC13025784
DOI
10.3390/genes17030294

Abstract (original English)

Background Pathogenic variants in KDM3B have been implicated as the cause of Diets-Jongmans syndrome (DIJOS), an autosomal-dominant disorder characterized by growth retardation, intellectual disability, facial dysmorphism and autism-spectrum disorder. However, only a limited number of cases have been reported. Methods The general characteristics of four patients were recorded, including clinical features, child development, neuropsychological assessment and therapeutic interventions. Whole exome sequencing (WES) was performed for potential genetic causes and interpretation of variants was performed in accordance with ACMG guidelines. Results All patients carried de novo variants in the KDM3B gene, namely, c.2832-3C>G, c.1188del p.(Glu397Argfs*21), c.4580T>C p.(Leu1527Pro), and c.3220dup p.(Glu1074Glyfs*48). Unlike other patients with DIJOS who presented with growth retardation, mild to moderate intellectual developmental disorder and facial dysmorphism, our patients mainly presented with growth retardation, while their neurodevelopment was either normal or mildly impaired. In addition, our patients received primarily supportive care. One patient treated with recombinant human growth hormone (rhGH) showed improvement in growth. Conclusions Our results broaden the mutational spectrum of KDM3B -related disorder and highlight the inter-patient variability of the clinical phenotype.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansGrowth DisordersHeterozygotePhenotypeMutationChild, PreschoolJumonji Domain-Containing Histone DemethylasesIntellectual DisabilityAutism Spectrum DisorderExome Sequencing

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research